Introduction
Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia, affecting 6% of the population over age 65. 1 It is a leading cause of stroke 2 and is associated with heart failure and premature death. 3 The rising prevalence 4 of AF has increased hospitalizations and healthcare costs. 5 Strokes in patients with AF are associated with greater mortality, morbidity, and longer hospital stays than that in those without AF. 2,6 -8 Randomized trials have shown that anticoagulation reduces the risk of stroke in patients with AF. 9 Warfarin is more effective than aspirin or placebo in reducing the risk of ischaemic stroke, but it carries a greater risk of major haemorrhage and requires regular monitoring. 9 The novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban are more expensive, but offer significant benefits over warfarin according to large randomized clinical trials conducted in a total of 50 578 patients. 10 -12 However, compared with placebo, all antithrombotic agents carry an increased haemorrhagic risk. 13 In patients with non-valvular AF (NVAF), the left atrial appendage (LAA) may be the most common site of thrombus formation. 14, 15 Left atrial appendage closure (LAAC) has been shown to be an effective means of stroke prevention in patients with NVAF 16 and is associated with significantly lower rates of mortality and haemorrhagic stroke than warfarin. 17 Recent data have suggested that in clinical trial populations, LAAC is a more expensive but cost-effective alternative to warfarin. 18 However, reconciling the cost-effectiveness of LAAC over a patient's lifetime with limited healthcare resources, and the requirement for shorter-term cost-saving, is challenging. It is important that we attempt to quantify the clinical benefits and costs at an early stage to help guide utilization and dissemination of the technology. The cost impact of LAAC based on real-world experience has not been studied before and these data may aid appropriate allocation of resources.
To provide an insight into the outcomes and costs of appendage closure in both a clinical trial setting and real-world practice, we present the results of a cost-impact analysis together with an LAAC registry study, outcomes of which inform parts of the cost analysis. Using a network meta-analysis, we modelled the long-term clinical outcomes and costs of randomized clinical trial data of LAAC compared with our real-world experience of LAAC and available pharmaceutical stroke prevention strategies to provide accurate and robust inputs for the cost analysis.
Methods

Registry study
The study included a cohort of consecutive patients with NVAF who underwent LAAC with the Watchman device (Boston Scientific, Marlborough, MA, USA) at the Royal Brompton & Harefield Hospitals (RBHH) between December 2009 and December 2013. Patients were offered the procedure according to the UK National Institute for Health and Care Excellence (NICE) 19 and European Society of Cardiology (ESC) 20 guidelines. Prior to commencing the study, the Institutional Clinical Practice Committee at the Royal Brompton & Harefield Hospitals approved the procedure. Subsequently, all patients were discussed and approved for LAAC by a multidisciplinary team. All patients gave written informed consent.
Device, procedure, and antithrombotic therapy
The technique of LAAC with the Watchman device has previously been described in detail. 16 Patients deemed suitable for medium-to longterm anticoagulation were maintained on warfarin with an INR of 2 -3 for the 4 weeks prior to their procedure. Those deemed unsuitable for medium-to long-term anticoagulation were initiated on dual platelet therapy (aspirin and clopidogrel) prior to their procedure. See Supplementary material online for details.
Follow-up
Follow-up was performed by outpatient visits at 1, 6, and 12 months and yearly thereafter. A transoesophageal echocardiogram (TOE) was performed in all patients at 6 weeks (anticoagulation suitable) or 3 months (anticoagulation unsuitable). For patients in whom antithrombotic therapy could not be stopped, a further TOE was performed to assess endothelialization and seal of the device.
Statistical analysis
Continuous data are presented as mean + SD, mean (95% confidence interval, CI), or median (interquartile range) depending on the distribution of data. Comparisons were made using Student's t-test or the Wilcoxon matched-pairs signed-rank test. A two-sided P,0.05 was considered statistically significant. All statistical data were analysed using Stata 12 (Statacorp, TX, USA).
Cost-impact model
We applied a validated model 21 to estimate long-term costs and clinical outcomes for the LAAC trial results, 16 RBHH cohort, and pharmacological alternatives. The model takes the perspective of the UK National Health Service (NHS) and has a 10-year time horizon. Costs are reported in 2015 British pounds and were discounted at an annual rate of 3.5%, in accordance with the UK Treasury 22 and NICE guidelines.
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All analyses were performed using Microsoft Excel (Microsoft, USA).
Modelled pharmacological comparators
Pharmacological comparators evaluated in the model were warfarin, dabigatran (110 and 150 mg twice daily), rivaroxaban, and apixaban for patients able to take oral anticoagulants (anticoagulation suitable group). Aspirin monotherapy and no antithrombotic therapy were evaluated for patients with relative contraindications to oral anticoagulants (anticoagulation unsuitable group). Effectiveness estimates were based on intention-to-treat analyses from 20 randomized studies, 13 which reflect outcomes of those on therapy as well as outcomes of those who discontinued.
Base case
Baseline characteristics for the modelled population and subgroups were matched for age, CHADS 2 , 24 CHA 2 DS 2 -VASc, 25 and HAS-BLED 26 scores, and anticoagulation suitability of patients from the RBHH cohort (Table 1) . Age-specific general population mortality rates were obtained from National Life Tables  27 and adjusted to account for the higher   mortality rates associated with AF  28 (Table 1) .
Model structure
Simplified model schematics are presented in Figures 1 (LAAC arm) and 2 (drug arm), and detailed in Supplementary material online.
Modelled clinical inputs
Inputs for the clinical trial of LAAC relative to warfarin (PROTECT AF LAAC) were calculated using the data from the PROTECT AF randomized controlled trial of the Watchman device and warfarin. 16 This permitted incorporation of LAAC into the network meta-analysis ( Table 2) . Data regarding 'whole group' outcomes of the RBHH LAAC arm of the analysis were taken from the RBHH cohort, as presented above. Inputs for the pharmacological comparators were estimated using the results of a published large network meta-analysis. 13 This provided data for stroke, major bleeding, and all-cause mortality.
Results from the PROTECT AF study 16 were selected as the study reports data from a completed pre-defined follow-up period and provides a more conservative estimate of LAAC event rates including complication rates associated with the initial learning stages of device implantation, compared with the recent PREVAIL study. 29 Inputs for patients unsuitable for anticoagulation were extrapolated using baseline characteristics of these patients from the RBHH cohort and applying the relative risks for PROTECT AF LAAC, aspirin, and no therapy.
No randomized data of LAAC currently exist for patients unsuitable for anticoagulation; however, published event rates are similar 30 to those in the randomized trial of patients suitable for anticoagulation (all stroke: 2.3% per 100 patient-years). 16 The anticoagulation unsuitable group has a higher baseline risk of stroke and bleeding, which has been accounted for in our analysis. However, other characteristics of these two patient groups are similar, 16, 27 with no other factors that would result in a substantively different relative risk of adverse events (including LAAC procedure-related adverse events) in these patient populations. Due to the overall low event rate in the RBHH cohort, there was an absence of certain events (stroke, major bleeding, or all-cause mortality) in each subgroup. We, therefore, used the combined event rate for the whole group when performing CHADS 2 , CHA 2 DS 2 -VASc, and anticoagulation unsuitable subgroup analyses with differential baseline risk profiles, in order to provide more accurate and meaningful analyses of 10-year outcomes and costs. Event rates from the RBHH registry were used for base case value and where RBHH events were zero, upper bound of the PROTECT AF 16 or ASAP study 30 event rates was used (vascular complications were reported in ASAP but not in PROTECT AF).
Modelled cost inputs
Patients incurred costs for treatment, including concomitant drug therapy in the LAAC arms, and for adverse events. Cost inputs were taken from the NHS Health Resource Group (HRG) 31 and NHS Drug Tariffs 32 ( Table 3) . Costs for post-acute stroke care and long-term disability were taken from the published literature. 33 
Sensitivity analysis
Probabilistic sensitivity analysis was used to assess the impact of uncertainty over input parameters on the model results. Five thousand iterations were drawn for each comparison. Distributions used 95% CIs where available and +20% of the mean where they were not. We also conducted a deterministic sensitivity analysis to investigate the influence of individual parameters and varied each parameter between the 95% CIs.
Results
Royal Brompton & Harefield Hospital patients undergoing left atrial appendage closure
The study included a total of 110 consecutive patients with NVAF who underwent 112 LAAC procedures (two patients underwent repeat LAAC as the first implantation attempt was unsuccessful due to complex anatomy). Baseline characteristics are summarized in Table 4 . Patients were followed for an aggregate of 223 patientyears. The mean follow-up per patient was 24.3 + 5.6 months. One patient was lost to follow-up.
Registry results and outcomes
The acute implantation success rate was 92% (103 of 112 procedures). One patient (0.9%) developed pericardial bleeding with tamponade later on the day of the procedure, requiring percutaneous drainage. There were no other complications prior to hospital discharge.
At 6 months, 87% (96 of 110 patients) of patients were able to reduce to aspirin monotherapy. By 12 months, 91% (100/110) of patients had discontinued primary antithrombotic therapy. Over the follow-up period, the annual rates of all-cause mortality, stroke, systemic embolism, and major bleeding were 1.79% (95% CI 0.49 -4.53%, 4 events/223 patient-years), 0.90% (0.11 -3.20%, 2/223 patient-years), 0%, and 0.90% (0.11 -3.20%, 2/223 patientyears), respectively (see Supplementary material online, Table S1 ). The four deaths were non-cardiac-related. See Supplementary material online for details.
The expected ischaemic stroke rate for this patient cohort based on their individual CHADS 2 scores, assuming no antithrombotic therapy, was 6.1% (5.5 -6.6%) per year. 24 On the basis of individual CHA 2 DS 2 -VASc scores, assuming no antithrombotic therapy, the expected ischaemic stroke rate was 6.3% (5.7 -6.9%). The expected major bleeding rate based on individual HAS-BLED scores assuming warfarin therapy was 7.6% (7.2-8.0%) per year. 26 Using modelled 1-year clinical event rates, the expected major bleeding rate using no antithrombotic therapy was 2.2% (0.9 -4.2%). The observed ischaemic stroke and major bleeding rates in the RBHH LAAC cohort, however, were both 0.90% (0.11 -3.20%) per year. There was, therefore, an 85% reduction in the expected rate of stroke (P , 0.001, Figure 3A ) and a 60% reduction in the expected rate of major bleeding events (P , 0.01, Figure 3B ), for the RBHH Annual cost of disability after the first year £10 250 £8200 £12 300 Gamma
LAAC, left atrial appendage closure. a As a national tariff for LAAC did not exist at the time of writing this article, we used the tariff with nearest approximation to LAAC (EA09Z: percutaneous interventions: percutaneous transluminal atrial septal defect/ventricular septal defect/patent foramen ovale closure and valve insertion) with an additional 30% uplift due to the higher costs for LAAC consumables.
LAAC patients compared with patients on no antithrombotic therapy.
Modelled 10-year clinical event projection
Model estimated clinical events are reported as the mean probabilistic sensitivity analysis results. RBHH's LAAC was predicted to have lower rates of ischaemic stroke and major bleeding, and PROTECT AF LAAC was predicted to have lower rates of all-cause mortality over 10 years when compared with the other agents ( Figure 4A-C and Table 5 ).
These benefits were most evident in the higher stroke risk (CHADS 2 .0-1 or CHA 2 DS 2 -VASc .3, Tables 6 and 7) and anticoagulation unsuitable subgroups. Clinical events (stroke, major bleeding, and death) in 8% of patients (both LAAC groups) who had unsuccessful implants and those who had peri-device gaps necessitating long-term antithrombotic therapy also contributed to the LAAC group event rates.
Cost-impact analysis
Model estimated costs are reported as the mean probabilistic sensitivity analysis results. See Supplementary material online for details.
Whole group
There is a high initial cost of LAAC, as with most implantable devices; however, this is offset by lower rates of ischaemic stroke, major bleeding, and death over 10 years when compared with the other agents ( Figure 4A -C and Table 5 ). Over a 10-year period, RBHH LAAC and PROTECT AF LAAC were cost-saving compared with all other treatment options ( Figure 5 ). Estimated cost-savings for RBHH LAAC ranged from £7194 (95% CI 2£1260 to £16 264) against dabigatran 110 mg to £1162 (2£5388 to £7061) against warfarin ( Table 6 ). For PROTECT AF LAAC, this cost-saving ranged from £4586 (2£4334 to £14 447) against dabigatran 110 mg to £1247 (2£5542 to £8000) against aspirin. However, based on PROTECT AF, LAAC appeared more costly than warfarin at 10 years [2£1447 (2£7790 to £3940)]. Cost parity was achieved between 4.9 and 8.4 years for RBHH LAAC ( Table 6 ) against all comparator treatments and 5.9 and 8.4 years for PROTECT AF LAAC against all comparator treatments except warfarin. The estimated probability that RBHH LAAC would be cost-saving at 10 years ranged between 92% relative to dabigatran 110 mg and 64% relative to warfarin (Table 6) . Similarly, the estimated probability that PROTECT AF LAAC would be cost-saving at 10 years ranged between 78% relative to dabigatran 110 mg and 63% relative to aspirin. Using CHA 2 DS 2 -VASc stroke risks, compared with each treatment option, LAAC achieved cost parity at an earlier stage than using CHADS 2 risks ( Figure 6 ).
Although this model was not designed to analyse beyond 10 years, extrapolation suggested that PROTECT AF LAAC would become cost-saving against warfarin between 12 and 13 years. CHADS 2 and CHA 2 DS 2 -VASc subgroups In the CHADS 2 0 -1 subgroup, warfarin, aspirin, and no therapy were less economical than LAAC over a 10-year period (see Supplementary material online, Figure S1 ). In the CHADS 2 LAAC, aspirin, and no therapy were the therapeutic options for anticoagulation unsuitable patients. Asterisks indicate that inputs for 'PROTECT AF LAAC-Anticoagulation Unsuitable' were modelled. LACC, left atrial appendage closure; AF, atrial fibrillation. Figure 3 (A) Expected annual rates of stroke in the study population based on CHADS 2 score, compared with the cumulative observed rates during the entire study period (mean, 95% CI). There was a significant reduction in the expected rates of stroke (88%, P , 0.001). (B) Expected annual rates of major bleeding events in the study population based on HAS-BLED score, compared with the cumulative observed rates during the entire study period (mean, 95% CI). There was a significant reduction in the expected rates of major bleeding events (60%, P , 0.01). LACC, left atrial appendage closure; AF, atrial fibrillation.
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Outcomes and costs of left atrial appendage closure relative to oral anticoagulation Accordingly, times to achieve cost parity were also shorter for LAAC in these high-risk subgroups (Tables 6 and 7) . Overall, LAAC in the CHADS 2 ≥3 subgroup was the most cost-saving group. In the CHA 2 DS 2 -VASc subgroups, RBHH LAAC and PRO-TECT AF LAAC were cost-saving against all comparators in the CHA 2 DS 2 -VASc .3 and CHA 2 DS 2 -VASc .5 subgroups, respectively (see Supplementary material online, Figures S6 -S8) . Ten-year cost-savings in the CHA 2 DS 2 -VASc ≤3 subgroups were similar to that of the CHADS 2 0-1 subgroup (Tables 6 and 7) . In addition, LAAC in the anticoagulation unsuitable subgroup was cost-saving within 6.5 years (CHADS 2 ) and 5.9 years (CHA 2 DS 2 -VASc) corresponding to aspirin and no therapy (see Supplementary material online, Figures S9 and S10) .
One-way sensitivity analysis demonstrated that total cost impact of LAAC was generally robust to changes in the parameters (see Supplementary material online for details).
Discussion
To our knowledge, this is the first cost-impact analysis using randomized controlled trial and real-world patient data to compare LAAC against currently available treatment options for the prevention of AF-related stroke and other clinical sequelae.
Cost-savings are seen with LAAC against all comparator treatments within 13 years utilizing data from both the PROTECT AF randomized controlled trial and within 9 years from real-world experience of LAAC. This relates to a cost-saving of 11 -43% (RBHH LAAC against all comparators) or 9 -27% (PROTECT AF LAAC against all comparators except warfarin) over 10 years. This is driven predominantly by cost-saving in patients with higher thromboembolic risk (CHADS 2 .0-1 and CHA 2 DS 2 -VASc .3) and those unsuitable for anticoagulation. In patients with a low thromboembolic risk (CHADS 2 0 -1 and CHA 2 DS 2 -VASc ≤3), warfarin, aspirin, and no therapy are more economical than LAAC over a 10-year period.
Baseline characteristics and procedural outcomes
The baseline characteristics of the RBHH cohort were similar to those of the two published clinical trials of LAAC (PROTECT AF 16 were higher in the RBHH cohort.
In the PROTECT AF study, 1945 of 4998 (39%) patients screened were ineligible according to clinical or echocardiographic criteria. However, we did not pre-select patients for inclusion in the RBHH cohort on the basis of their cardiac imaging.
Despite having a population with higher baseline risk and lower patient pre-selection, our procedural and device-related adverse events were significantly lower than those in the published studies [0.9 vs. 8.7% (PROTECT AF, 16 of improved procedural technique that has been developed with experience, as has been previously reported. 16 The observed stroke and major bleeding rates for this patient cohort were both lower than would be expected based on their CHADS 2 and HAS-BLED scores and assuming no antithrombotic therapy ( Figure 3A and B) . Modelled 10-year event rates also demonstrated the largest risk reduction in stroke (range 6.9% vs. PROTECT AF LAAC to 38.8% vs. no therapy) and major bleeding (range 10.5% vs. no therapy to 49.6% vs. warfarin) with the RBHH cohort data. The four non-cardiac-related deaths resulted in an annual mortality risk of 1.8%, resulting in a modelled 10-year all-cause mortality probability of 25.7%. Although higher than PROTECT AF LAAC data and that of the NOACs, the 10-year all-cause mortality risk reduction for the RBHH LAAC cohort ranged from 7.0% vs. warfarin to 22.5% vs. no therapy.
These comparisons suggest that RBHH registry outcomes are broadly comparable to published randomized controlled trial data 16, 29 and in line with a recent multicentre registry study. 34 Therefore, even in a real-world setting, the use of LAAC can result in reductions in stroke and major bleeding for patients with NVAF, when compared with existing pharmacological alternatives. In the UK, NICE guidelines 19 at the time of our study allowed for LAAC to be considered in patients able to tolerate warfarin with a high bleeding risk (HAS-BLED ≥3) and those unsuitable for anticoagulation. Interestingly, these guidelines have recently changed, 35 and now LAAC is recommended only in patients unsuitable for anticoagulation, in line with existing ESC guidelines. 20 However, a recent European expert consensus statement on LAAC recommended patient selection to be more inclusive, 36 as per the original NICE guidelines. Although national and international guidelines may give differing recommendations on patient selection for LAAC, it should be borne in mind that the only published randomized controlled trial data for LAAC are for patients who are suitable for long-term anticoagulation.
16,29
Cost-impact analysis
There is a paucity of health economic data for LAAC. A Canadian economic evaluation estimated that the lifetime healthcare costs with LAAC would be greater than with warfarin ($27 003 compared with $21 429), but that the estimated health benefits would justify this additional expenditure: incremental cost-effectiveness ratio of $41 565 per quality-adjusted life year gained, which is within the range and usually considered to be cost-effective in Canada. 18 A European budget impact analysis 21 across a 10-year time horizon estimated that LAAC was less expensive than dabigatran 150 mg at 8 years (E15 061 vs. E16 184). At 10 years, it was only 10% more expensive than warfarin (E16 736 vs. E15 168). As a device-based treatment, the costs of LAAC are almost entirely procedure based, whereas the treatment and complication costs of pharmaceutical agents accrue year on year.
The model estimated that LAAC had a high probability of being cost-saving over a period of 4 -13 years, depending on the comparator. This is primarily a reflection of the significant reduction in major events and the substantial savings that were achieved through the reduction in long-term disability as a consequence. The exceptions were in the sub-analysis of the CHADS 2 0 -1 and CHA 2 DS 2 -VASc ≤3 groups, in which warfarin, aspirin, and no therapy were economical compared with LAAC over 10 years and the CHADS 2 2 group in which warfarin was economical compared with LAAC. Subgroup analyses demonstrated that LAAC had the most clinical and economic benefit in the groups with higher baseline stroke (see Supplementary material online, Figure S11 ) and bleeding risk.
The network meta-analysis provides a robust method for the indirect comparison of different treatment options by standardizing the relative risks of clinical events through accounting for differences in the patient populations of each respective study.
To the best of our knowledge, this is the only cost analysis of these particular therapies that has utilized network meta-analysis data. 13 This allowed accurate comparative assessments of the costs associated with each therapeutic option.
In comparison with the aforementioned studies, 18, 21 there are several areas upon which our study builds. Foremost, the model has been populated with real-world patient data from two UK centres performing LAAC. Secondly, it provided the flexibility to investigate the cost impact of LAAC compared with an extensive range of other established and newly available treatment strategies provided to the UK patients. Thirdly, we incorporated standardized relative risks from a network meta-analysis to more accurately account for differences in the patient populations of the included clinical trials. Fourthly, stroke risk and anticoagulation unsuitable subgroup analyses were performed. The event rates for patients unsuitable for anticoagulation are indirectly extrapolated from the network meta-analysis 13 using data for LAAC in patients suitable for anticoagulation. 16 Apart from differences in baseline stroke and bleeding risk, which have been accounted for in our analysis, this subgroup of patients are similar enough to patients suitable for anticoagulation (age 72. However, there is some inherent uncertainty in the anticoagulation unsuitable group due to the lack of direct randomized evidence in this population. This is an area that requires further research.
Our study demonstrates that with the improvements in procedural safety and implantation technique that comes with increasing experience, LAAC results can be more favourable than comparator treatments. This analysis demonstrates that the high upfront costs of LAAC may be outweighed by lower long-term event rates, resulting in reduced costs to the healthcare system over 10 years compared with oral anticoagulants. This is the case for both data from the PROTECT AF randomized controlled trial and from realworld experience of LAAC. Within a climate of financial constraint, on the basis of this analysis, LAAC may be recommended for subgroups where benefit may be greater, such as in those with higher stroke risk.
With the diversity of established and NOAC therapies and LAAC devices available, our results and cost-impact analysis add considerably to the evidence base available to clinicians and healthcare commissioners to help choose the appropriate therapeutic option for their patient population.
Limitations
Although all clinical data for the RBHH cohort were prospectively collected at both centres, this study was not randomized and is therefore subject to known biases of non-randomized registry studies. Patient's quality of life was not considered as this analysis was intended to explore the healthcare costs of LAA closure.
The key modelling assumption is that of continued benefit with on-going anticoagulation treatment and with LAAC. However, as with any economic model, results rest on important assumptions and limited data. This is particularly important in the analysis of technologies in the early stages of assessment where the data are inevitably less well developed than at later stages. This a well-known dilemma in the health economic field where early assessments of health technologies are important to prevent on the one hand, premature dissemination or, on the other, lack of investment in further research or utilization of the technology.
The cost difference in LAAC to comparator treatments over 10 years is most sensitive to the LAAC stroke rates (see Supplementary material online, Figures S12 -S14) . Therefore, higher stroke rates with LAAC could result in an unfavourable long-term cost profile. However, our analysis shows that even with the higher event rates seen in the PROTECT AF study compared with our registry data and other recently published registry data, 34 the costs of LAAC were lower than all comparator treatments, except warfarin, at 10 years. Finally, this analysis is based on use of the Watchman device and thus may not reflect the cost impact of other LAAC devices.
Conclusions
The present study is the first cost-impact analysis using real-world patient data to compare LAAC with trial data for currently available treatment options in the prevention of NVAF-related stroke and other clinical sequelae.
Treatment with LAAC can reduce the risk of stroke, major bleeding, and death compared with other therapeutic strategies. These clinical benefits may offset the additional upfront costs of the device and of potential procedure-related adverse events. The economic and clinical benefits of LAAC are most apparent in treating patients with higher baseline thromboembolic risk and those who are anticoagulation unsuitable.
In this analysis, cost-parity is achieved against all comparators within 13 years. Furthermore, LAAC might still be a cost-effective option for patients with a life expectancy shorter than the time to cost parity, if it improved their life expectancy and/or quality of life.
Our findings highlight the importance of taking a long-term perspective in preventive healthcare to maximize population health gains from limited resources.
